Vanta Bioscience (BOM:540729) Debt-to-Equity : 4.83 (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Vanta Bioscience Debt-to-Equity?

Vanta Bioscience's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ₹137.02 Mil. Vanta Bioscience's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ₹521.18 Mil. Vanta Bioscience's Total Stockholders Equity for the quarter that ended in Sep. 2024 was ₹136.30 Mil. Vanta Bioscience's debt to equity for the quarter that ended in Sep. 2024 was 4.83.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Vanta Bioscience's Debt-to-Equity or its related term are showing as below:

BOM:540729' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.58 Med: 1.36 Max: 4.83
Current: 4.83

During the past 8 years, the highest Debt-to-Equity Ratio of Vanta Bioscience was 4.83. The lowest was 0.58. And the median was 1.36.

BOM:540729's Debt-to-Equity is ranked worse than
98.96% of 193 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.23 vs BOM:540729: 4.83

Vanta Bioscience Debt-to-Equity Historical Data

The historical data trend for Vanta Bioscience's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vanta Bioscience Debt-to-Equity Chart

Vanta Bioscience Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Equity

Get a 7-Day Free Trial

0.74

1.50

1.87

3.26

4.02

Vanta Bioscience Semi-Annual Data
	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial											2.20	3.26	3.36	4.02	4.83

Competitive Comparison of Vanta Bioscience's Debt-to-Equity

For the Diagnostics & Research subindustry, Vanta Bioscience's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vanta Bioscience's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Vanta Bioscience's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Vanta Bioscience's Debt-to-Equity falls into.

Vanta Bioscience Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Vanta Bioscience's Debt to Equity Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(123.144	+	488.014)	/	151.989
	=	4.02

Vanta Bioscience's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(137.024	+	521.183)	/	136.3
	=	4.83

Vanta Bioscience (BOM:540729) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Vanta Bioscience Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Vanta Bioscience's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Vanta Bioscience Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Vanta Bioscience Ltd (BOM:540729) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 02/G/308/G, Umajay Complex, No. 3/FF/SF/1-20-248, Rasoolpura, Secunderabad, TG, IND, 500003

Website

https://www.vantabio.com

Vanta Bioscience Ltd is a full-service preclinical contract research organization. It is engaged in the provision of testing and contract research in the fields of clinical research, pre-clinical research, biopharma services, analytical testing and research, and environmental studies. It offers toxicology, batch release tests, biocompatibility studies, chemical safety, and diet formulation services.

Vanta Bioscience Headlines

No Headlines